- [Alt + 0] - Startseite
- [Alt + 1] - Navigation
- [Alt + 2] - Inhalt
- [Alt + 3] - Contact
- [Alt + 4] - Sitemap
- [Alt + 5] - Search
Navegación con Teclas de Acceso
Noticias Recientes
Octapharma research cooperation further elucidates mechanism of action of octagam
30.10.2009
Octapharma remains committed to researching the mechanisms of action of IVIG and its efficacy in various indications with the goal to improve treatment in immune mediated conditions and to gain registrations for additional...
Octapharma Group and Fresenius Kabi enter into an Exclusive License, Development and Supply Agreement for a HESylated recombinant protein
29.10.2009
Octapharma Group and Fresenius Kabi enter into an Exclusive License, Development and Supply Agreement for a HESylated recombinant protein. Octapharma Group and Fresenius Kabi have signed a License, Development and Supply...
Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
02.10.2009
LACHEN, SWITZERLAND (October 2, 2009) – Through June 2009, Octapharma AG realized a record turnover of €536M, compared to €422M as of year-to-date June 2008, an increase of 27%.The cost of sales increased proportionally...
The UK Blood Advisory Group(SaBTO) recommends Variant Creutzfeld Jacob Disease (vCJD) risk-reduction strategy for fresh frozen plasma (FFP) Octapharma develop OctaplasLG® to offer a solution.
09.09.2009
SaBTO, (Safety of Blood, Tissue and Organs) the committee set up to advise the UK government on matters relating to blood safety, have issued guidelines that will further increase the safety of FFP by introducing measures to...
Press Release - Octapharma Targeting the Major Risk of Hemophilia Treatment – FVIII Antibodies
31.08.2009
ISTH Symposia Discuss Prevention and Eradication of FVIII Inhibitors and Introduce First Recombinant FVIII Produced From a Human Cell Line
Press Release - Octapharma comments on the CADTH Report on cost-effectiveness of Octaplas®
08.05.2009
The Canadian Agency for Drugs and Technologies in Health (CADTH) recently published on their website the second version of their report entitled: “Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting...
Press release - Swine Influenza Virus (SIV) Outbreak and Implications in the Transfusion of the Biopharmaceutical Pooled and Virally Inactivated Plasma for Transfusion Octaplas®
29.04.2009
The outbreak of the swine flu virus in Mexico, US and Canada as well as some European countries may have direct implications in the transfusion of blood components.The Paul Ehrlich Institute (PEI) in Germany has issued...